Bristol-Myers Ends Phase 3 Melanoma Study Early Due To Superior Overall Survival

June 25, 2014 4:30 AM

6 0

Drugmaker Bristol-Myers Squibb Co. (BMY: Quote) Tuesday said a late-stage study of Nivolumab was stopped early as it demonstrated superior overall survival in certain melanoma patients compared to dacarbazine.

In the randomized blinded comparative Phase 3 study evaluating nivolumab with dacarbazine or DTIC in patients with previously untreated BRAF wild-type advanced melanoma, an analysis conducted by the independent Data Monitoring Committee or DMC showed evidence of superior overall survival in patients...

Also read: Deutsche Bank Gets a Much-Needed Boost Working for Big Tobacco

Read more

To category page